Malignant Breast Neoplasm — Trials

Malignant Breast Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,628
Recruiting: 1,398
Ph III recruiting: 152
Growth YoY: +22.4%
Industry share: 18%
Top sponsor: Fudan University
Termination share: 25.6%
Trials / 1,000 deaths: 61.5 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,368)

clinicaltrialsPublishedShowing 101–150 of 3,552 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04721977	A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)	active not recruiting	Phase 2	66	PfizerINDUSTRY	3	Sep 10, 2026	clinicaltrials
NCT05852691	A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer	active not recruiting	Phase 2	83	Hoffmann-La Roche